Literature DB >> 7999797

Structural organization of the gene for CD40 ligand: molecular analysis for diagnosis of X-linked hyper-IgM syndrome.

M Shimadzu1, H Nunoi, H Terasaki, R Ninomiya, M Iwata, S Kanegasaka, I Matsuda.   

Abstract

CD40 ligand (CD40L) on activated T cells plays a crucial role for Ig heavy-chain class switching and the mutation of the gene for this ligand in the X-chromosome causes immunodeficiency with hyper-IgM (X-HIM). We isolated and characterized the human genomic clone for CD40 L to obtain information about the transcriptional regulatory regions of the gene and to develop a molecular diagnostic method for X-HIM patients. The genomic DNA isolated was over 12 kb long containing 5 exons that cover full sequence of mRNA for the ligand. DNA motif analysis based on transcription factor database revealed the presence of a GATA 1 box at around -265 bp. The typical TATA box, CAT site or GC rich region was not found in the 5' flanking region. However, two possible TATA like sequences were found at around -27 and -136 bp. Using the oligonucleotide primers corresponding to the introns, we performed a PCR-SSCP analysis of each exon from a patient with X-HIM syndrome and detected abnormality in exon 5. When sequenced, dinucleotide deletion in this exon was found in the patient and in one X allele of his mother as the only different sequence from that of the control gene. This procedure is simple and could be used for diagnosis of the X-HIM syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7999797     DOI: 10.1016/0167-4781(94)00179-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Non-functional immunoglobulin G transcripts in a case of hyper-immunoglobulin M syndrome similar to type 4.

Authors:  John M Darlow; Alex M Farrell; David I Stott
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

Review 3.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Hyper-immunoglobulin M syndrome caused by a mutation in the promotor for CD40L.

Authors:  Erna Van Hoeyveld; Ping-Xia Zhang; Kris De Boeck; Ramsay Fuleihan; Xavier Bossuyt
Journal:  Immunology       Date:  2007-01-17       Impact factor: 7.397

5.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease.

Authors:  J Wu; J Wilson; J He; L Xiang; P H Schur; J D Mountz
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

6.  NF-kappaB is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cells.

Authors:  M Srahna; J E Remacle; K Annamalai; S Pype; D Huylebroeck; M A Boogaerts; P Vandenberghe
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

7.  Functional CD40 ligand is expressed by T cells in rheumatoid arthritis.

Authors:  K P MacDonald; Y Nishioka; P E Lipsky; R Thomas
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 8.  CD154 transcriptional regulation in primary human CD4 T cells.

Authors:  Randy Q Cron
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome.

Authors:  Q Lin; J Rohrer; R C Allen; M Larché; J M Greene; A O Shigeoka; R A Gatti; D C Derauf; J W Belmont; M E Conley
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

10.  Generation of mice with conditional ablation of the Cd40lg gene: new insights on the role of CD40L.

Authors:  Angélica Horrillo; Tomás Fontela; Elena G Arias-Salgado; Dolores Llobat; Gracia Porras; Matilde S Ayuso; Consuelo González-Manchón
Journal:  Transgenic Res       Date:  2013-09-13       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.